JP2008540445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540445A5 JP2008540445A5 JP2008510224A JP2008510224A JP2008540445A5 JP 2008540445 A5 JP2008540445 A5 JP 2008540445A5 JP 2008510224 A JP2008510224 A JP 2008510224A JP 2008510224 A JP2008510224 A JP 2008510224A JP 2008540445 A5 JP2008540445 A5 JP 2008540445A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- site
- aav vector
- aav2
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67705705P | 2005-05-02 | 2005-05-02 | |
| US60/677,057 | 2005-05-02 | ||
| US68580805P | 2005-05-31 | 2005-05-31 | |
| US60/685,808 | 2005-05-31 | ||
| PCT/US2006/017242 WO2006119458A1 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201138A Division JP2014037418A (ja) | 2005-05-02 | 2013-09-27 | 神経代謝性疾患のための遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540445A JP2008540445A (ja) | 2008-11-20 |
| JP2008540445A5 true JP2008540445A5 (enExample) | 2009-07-09 |
| JP5829372B2 JP5829372B2 (ja) | 2015-12-09 |
Family
ID=37308324
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510224A Active JP5829372B2 (ja) | 2005-05-02 | 2006-05-02 | 神経代謝性疾患のための遺伝子治療 |
| JP2013201138A Pending JP2014037418A (ja) | 2005-05-02 | 2013-09-27 | 神経代謝性疾患のための遺伝子治療 |
| JP2015197051A Active JP6338560B2 (ja) | 2005-05-02 | 2015-10-02 | 神経代謝性疾患のための遺伝子治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201138A Pending JP2014037418A (ja) | 2005-05-02 | 2013-09-27 | 神経代謝性疾患のための遺伝子治療 |
| JP2015197051A Active JP6338560B2 (ja) | 2005-05-02 | 2015-10-02 | 神経代謝性疾患のための遺伝子治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10632213B2 (enExample) |
| EP (4) | EP2420256B1 (enExample) |
| JP (3) | JP5829372B2 (enExample) |
| CN (4) | CN104306986A (enExample) |
| AT (1) | ATE525092T1 (enExample) |
| AU (1) | AU2006243776A1 (enExample) |
| BR (1) | BRPI0611379A2 (enExample) |
| CA (2) | CA2607173C (enExample) |
| ES (1) | ES2887076T3 (enExample) |
| IL (2) | IL187078A (enExample) |
| PL (4) | PL2420256T3 (enExample) |
| PT (4) | PT2420256T (enExample) |
| WO (1) | WO2006119458A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3302529B2 (ja) | 1995-04-28 | 2002-07-15 | 株式会社クボタ | ポンプ吸水槽の整流装置 |
| PT2420256T (pt) | 2005-05-02 | 2016-09-13 | Genzyme Corp | Terapia genética para distúrbios neurometabólicos |
| BRPI0611540A2 (pt) * | 2005-05-02 | 2010-09-21 | Genzyme Corp | terapia de gene para distúrbios de espinha dorsal |
| BRPI0711965A2 (pt) | 2006-06-07 | 2012-01-24 | Genzyme Corporation | terapia de gene para esclerose lateral amiotrófica e outras enfermidades da medula espinal |
| PT3252161T (pt) | 2007-06-06 | 2022-02-01 | Genzyme Corp | Terapia genética para doenças do armazenamento lisossomal |
| EP2687609B1 (en) | 2008-11-10 | 2017-01-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for treating solid tumor |
| SG10202109219SA (en) | 2009-05-02 | 2021-10-28 | Genzyme Corp | Gene therapy for neurodegenerative disorders |
| US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
| WO2012145646A1 (en) * | 2011-04-20 | 2012-10-26 | Miguel Sena-Esteves | Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN112553229A (zh) | 2014-11-05 | 2021-03-26 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
| EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| NZ772772A (en) | 2015-02-10 | 2024-12-20 | Genzyme Corp | Enhanced delivery of viral particles to the striatum and cortex |
| US11046746B2 (en) | 2015-03-26 | 2021-06-29 | Suzhou Auzone Biological Technology Co., Ltd | Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US11027024B2 (en) | 2015-05-29 | 2021-06-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics, Inc. | composições e métodos de tratamento da doença de huntington |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN111108198A (zh) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| EP3635009B1 (en) | 2017-06-07 | 2026-02-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| CN111479924B (zh) | 2017-10-16 | 2024-06-14 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症(als)的治疗 |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| IL276464B2 (en) | 2018-02-07 | 2026-01-01 | Regeneron Pharma | Methods and compositions for administering therapeutic protein |
| AU2019268330A1 (en) | 2018-05-15 | 2020-11-26 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| MA52626A (fr) | 2018-05-17 | 2021-03-24 | Regeneron Pharma | Anticorps anti-cd63, conjugués et leurs utilisations |
| EP3856762A1 (en) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| KR20240126916A (ko) * | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8303626D0 (sv) | 1983-06-23 | 1983-06-23 | Kabigen Ab | A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| DE69433592T2 (de) | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| WO1995028493A1 (en) | 1994-04-13 | 1995-10-26 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
| WO1997039789A1 (en) | 1996-04-22 | 1997-10-30 | Medtronic, Inc. | Two-stage angled venous cannula |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| US6582692B1 (en) * | 1999-11-17 | 2003-06-24 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| DE60115070T2 (de) | 2000-09-18 | 2006-07-27 | Genzyme Corp., Cambridge | Expressionsvektoren mit hybriden ubiquitin-promotoren |
| US20030050273A1 (en) * | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
| US7232670B2 (en) * | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| WO2003052051A2 (en) | 2001-12-17 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
| US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
| EP1478236B1 (en) | 2001-12-21 | 2009-02-11 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
| AU2003220115A1 (en) * | 2002-05-20 | 2003-12-12 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
| PL1620133T3 (pl) * | 2003-05-01 | 2016-05-31 | Genzyme Corp | Terapia genowa dla zaburzeń neurometabolicznych |
| US20040258666A1 (en) * | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
| US7740168B2 (en) | 2003-08-18 | 2010-06-22 | Visa U.S.A. Inc. | Method and system for generating a dynamic verification value |
| AU2003272868A1 (en) | 2003-10-15 | 2005-04-27 | Agtc Gene Technology Company Ltd. | Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors |
| EP1716870A1 (en) | 2005-04-29 | 2006-11-02 | Bracco Imaging S.p.A. | MRI contrast agents endowed with concentration independent responsiveness |
| BRPI0611540A2 (pt) | 2005-05-02 | 2010-09-21 | Genzyme Corp | terapia de gene para distúrbios de espinha dorsal |
| PT2420256T (pt) | 2005-05-02 | 2016-09-13 | Genzyme Corp | Terapia genética para distúrbios neurometabólicos |
| EP1986661B1 (en) | 2006-02-08 | 2018-08-29 | Genzyme Corporation | Gene therapy for niemann-pick disease type a |
| KR20200016407A (ko) | 2011-05-16 | 2020-02-14 | 젠자임 코포레이션 | Ｃｘｃｒ４ 길항제의 용도 |
| TWI821227B (zh) | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
-
2006
- 2006-05-02 PT PT111696332T patent/PT2420256T/pt unknown
- 2006-05-02 AU AU2006243776A patent/AU2006243776A1/en not_active Abandoned
- 2006-05-02 ES ES19153520T patent/ES2887076T3/es active Active
- 2006-05-02 PL PL11169633.2T patent/PL2420256T3/pl unknown
- 2006-05-02 EP EP11169633.2A patent/EP2420256B1/en active Active
- 2006-05-02 PT PT06759081T patent/PT1879624E/pt unknown
- 2006-05-02 EP EP16162716.1A patent/EP3058959B1/en active Active
- 2006-05-02 PT PT16162716T patent/PT3058959T/pt unknown
- 2006-05-02 CN CN201410483749.6A patent/CN104306986A/zh active Pending
- 2006-05-02 EP EP19153520.2A patent/EP3520823B1/en active Active
- 2006-05-02 EP EP06759081A patent/EP1879624B1/en active Active
- 2006-05-02 CA CA2607173A patent/CA2607173C/en active Active
- 2006-05-02 WO PCT/US2006/017242 patent/WO2006119458A1/en not_active Ceased
- 2006-05-02 CN CNA2006800237754A patent/CN101212988A/zh active Pending
- 2006-05-02 PL PL19153520T patent/PL3520823T3/pl unknown
- 2006-05-02 PL PL16162716T patent/PL3058959T3/pl unknown
- 2006-05-02 JP JP2008510224A patent/JP5829372B2/ja active Active
- 2006-05-02 PL PL06759081T patent/PL1879624T3/pl unknown
- 2006-05-02 PT PT19153520T patent/PT3520823T/pt unknown
- 2006-05-02 CN CN201710506914.9A patent/CN107362371A/zh active Pending
- 2006-05-02 BR BRPI0611379-6A patent/BRPI0611379A2/pt not_active Application Discontinuation
- 2006-05-02 CN CN201611031204.7A patent/CN107007842A/zh active Pending
- 2006-05-02 AT AT06759081T patent/ATE525092T1/de not_active IP Right Cessation
- 2006-05-02 CA CA2998603A patent/CA2998603C/en active Active
-
2007
- 2007-11-01 IL IL187078A patent/IL187078A/en not_active IP Right Cessation
- 2007-11-02 US US11/934,325 patent/US10632213B2/en active Active
-
2013
- 2013-09-27 JP JP2013201138A patent/JP2014037418A/ja active Pending
-
2015
- 2015-06-03 IL IL239167A patent/IL239167A0/en unknown
- 2015-10-02 JP JP2015197051A patent/JP6338560B2/ja active Active
-
2020
- 2020-03-03 US US16/808,206 patent/US11957765B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540445A5 (enExample) | ||
| US11957765B2 (en) | Gene therapy for neurometabolic disorders | |
| JP2009526067A5 (enExample) | ||
| Zhang et al. | Several rAAV vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system | |
| Cheng et al. | Gene therapy progress and prospects: gene therapy of lysosomal storage disorders | |
| Passini et al. | Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of β-glucuronidase-deficient mice | |
| JP6312771B2 (ja) | 神経代謝性疾患についての遺伝子治療 | |
| EP3498851B1 (en) | Cns gene delivery using peripheral administration of aav vectors | |
| TWI547288B (zh) | 用於治療疾病之載體及序列 | |
| Miyake et al. | Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors | |
| JP2016503405A5 (enExample) | ||
| EA036394B1 (ru) | Псевдотипированный вектор на основе аденоассоциированного вируса aav-5 для генной терапии неврологических заболеваний | |
| WO2005120581A2 (en) | Gene therapy for neurometabolic disorders | |
| Hironaka et al. | Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector | |
| Gomez Limia et al. | Emerging perspectives on gene therapy delivery for neurodegenerative and neuromuscular disorders | |
| Ruzo et al. | Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice | |
| Cardone | Prospects for gene therapy in inherited neurodegenerative diseases | |
| US20230277687A1 (en) | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy | |
| Weismann | Approaches and Considerations Towards a Safe and Effective Adeno-Associated Virus Mediated Therapeutic Intervention for GM1-Gangliosidosis: A Dissertation | |
| Nandi et al. | Revolutionizing Gene Therapy: An Explicative Review on Engineering Adeno-associated Virus Vectors | |
| McCarty et al. | Gene Therapy for Neurodevelopmental Disorders | |
| Murlidharan¹ et al. | Biology of adeno-associated viral vectors in the central | |
| Cearley | Adeno-associated virus vector mediated correction of a neurogenetic disease: Influence of the vector capsid on dispersal of a therapeutic gene within the central nervous system | |
| Broekman | Discussion and conclusion | |
| RU2019117062A (ru) | Композиции, способы и применения переноса генов для лечения нейродегенеративных заболеваний |